Plasma fractionation issues

Biologicals - Tập 37 - Trang 88-93 - 2009
Albert Farrugia1, Theo Evers2, Pierre-Francois Falcou3, Thierry Burnouf4, Luiz Amorim5, Sylvia Thomas6
1Blood and Tissues Unit, Office of Devices, Blood and Tissues, Therapeutic Goods Administration, PO Box 100 Woden, ACT 2606, Australia
2International Plasma Fractionation Association (IPFA), Amsterdam, The Netherlands
3LFB Biotechnologies, Lille, France
4Human Protein Process Sciences (HPPS), Lille, France
5Hemobras, Brasilia, Brazil
6Brazilian Federation of Hemophilia, Sao Paulo, Brazil

Tài liệu tham khảo

Burnouf, 2007, Modern plasma fractionation, Transfus Med Rev, 21, 101, 10.1016/j.tmrv.2006.11.001 Farrugia, 2004, Plasma for fractionation: safety and quality issues, Haemophilia, 10, 334, 10.1111/j.1365-2516.2004.00911.x Burnouf, 2000, Reducing the risk of infection from plasma products: specific preventative strategies, Blood Rev, 14, 94, 10.1054/blre.2000.0129 Farrugia, 2005, International movement of plasma and plasma contracting, Dev Biol (Basel), 120, 85 CHMP, 2004 CHMP, 2004 WHO, 2005 2004 Burnouf, 2007, Plasma fractionation in the world: current status, Transfus Clin Biol, 14, 41, 10.1016/j.tracli.2007.04.002 <http://bpreco.saude.gov.br/bprefd/owa/consulta.inicio> [accessed 25.08.07]. O'Mahony, 2006 Albert Farrugia. Guide for the assessment of clotting factor concentrates. © World Federation of Hemophilia. PDF file at <www.wfh.org>; 2003. Comprasnet (for acquisition of goods and services by federal government). <www.comprasnet.gov.br>. 2005 Brooker, 2005